Abstracts tagged "rheumatic disease and viruses"

Abstract Number: 1319 • 2016 ACR/ARHP Annual Meeting
Chikungunya Fever in Patients on Biological and on Conventional Dmards Therapy – Results from the Brazilian Register Biobadabrasil
Aline Ranzolin¹, Angela Duarte², Claudia Marques³, Laurindo Rocha Jr⁴, Samia Araujo de Souza Studart⁵, José Caetano Macieira⁶, Monica Valeria Siqueira S de Vechi⁶, Lina Oliveira de Carvalho⁶, Ines Guimarães da Silveira⁷, Ieda Maria Magalhães Laurindo⁸ and BiobadaBrasil, ¹Rheumatology, Instituto de Medicina Integral Professor Fernando Figueira, Recife, Brazil, ²Internal Medicine, Hospital das Clínicas - UFPE, Recife, Brazil, ³Hospital das Clínicas, Universidade Federal de Pernambuco, Recife - PE, Brazil, ⁴Rheumatology, Instituto de Medicina Integral Professor Fernando Figueira - IMIP, Recife, Brazil, ⁵Reumatologia, Hospital Geral de Fortaleza, Fortaleza, Brazil, ⁶Reumatologia, Hospital Federal de Sergipe, Aracaju, Brazil, ⁷Reumatologia, Pontificia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil, ⁸Internal Medicine - Rheumatology, Faculdade de Medicina da Universidade Nove de Julho, São Paulo, Brazil
Background/Purpose: Chikungunya fever (CHIKF) is a systemic arboviral disease manifesting with fever, acute arthritis and rash. The acute symptoms can last for days but…
Abstract Number: 1357 • 2015 ACR/ARHP Annual Meeting
Cytomegalovirus (CMV) Infections in Patients with Rheumatic Diseases: Experience of a Referral Center
Yusuf Ziya Sener¹, Burak Yasin Aktas¹, Abdulsamet Erden², Levent Kilic², Berkan Armagan², Ahmet Cagkan Inkaya³, Omer Karadag², Sule Apras Bilgen² and Sedat Kiraz², ¹Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey, ²Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ³Infection Disease, Hacettepe University Faculty of Medicine, Ankara, Turkey
Background/Purpose: CMV is a ubiquitous herpes virus associated with significant immunosuppression. Immunosuppressive treatments and ageing is well known risk factors for CMV reactivation. There are…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].